Skip to main content
Clinical Trials/NL-OMON30421
NL-OMON30421Not yet recruitingPhase 4

The METEX Study: methotrexate versus expectant management in women with ectopic pregnancy - METEX Study

Academisch Medisch Centrum0 sites72 target enrollmentStarted: TBDLast updated:
Conditions

Trial Snapshot

Phase
Phase 4
Status
Not yet recruiting
Enrollment
72

Study Overview

Brief Summary

No summary available.

Study Design

Study Type
Interventional

Eligibility Criteria

Ages
18 to 99 (—)

Inclusion Criteria

  • All hemodynamically stable patients >= 18 years with either an ectopic pregnancy (a visible ectopic pregnancy or an ectopic mass on transvaginal sonography) and a plateauing serum hCG concentration < 1,500 IU/L or with a Pregnancy of Unknown Location (PUL) and a plateauing serum hCG concentration < 2,000 IU/L (persisting PUL).

Exclusion Criteria

  • Patients with a viable ectopic pregnancy, signs of tubal rupture and/or active intra abdominal bleeding or abnormalities in liver or renal function or in full blood count.

Investigators

Similar Trials

The METEX Study: methotrexate versus... | Clinical Trial